Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benfotiamine→

Benfotiamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
22457-89-2
Molecular formula
C19H23N4O6PS
Molecular weight
466.4 g/mol
Drug class
Synthetic lipid-soluble thiamine (vitamin B1) derivative
Mechanism of action
Converted to thiamine and thiamine diphosphate (TPP), the cofactor for transketolase and other thiamine-dependent enzymes. Experimental data suggest improved transketolase activity may divert glycolytic intermediates away from advanced-glycation and other hyperglycaemia-related pathways; clinical disease-modifying effects are not established.
Indications / reported uses
  • Used as a thiamine derivative supplement in countries where authorised; use for diabetic neuropathy or other conditions should not be presented as an established approved indication without a specific product label

Sources: PubMed — Benfotiamine clinical evidence and pharmacology · NLM MeSH — Benfotiamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benfotiamine Environmental Risk Assessment (ERA) (the Benfotiamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.